Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polymerized olive pollen immunotherapy for olive pollen allergic rhinitis/rhinoconjunctivitis
2026-526390-41-00Phase 3Authorised
- Sponsor
- Inmunotek
- Start
- Sep 2026
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Olea europaea pollen polymerized extract in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and asthma (2 arms), sponsored by Inmunotek. Primary endpoint: Mean daily rhinitis/rhinoconjunctivitis combined symptom and medication score during peak olive pollen season. Planned start Sep 2026; status: authorised.
02
Drugs
Olea europaea pollen polymerized extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on 2026-526390-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526390-41-00.